TCGA-55-8299-01A-11R-2287-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.610
- INTERFERON_GAMMA_RESPONSE+0.610
- ALLOGRAFT_REJECTION+0.580
- IL6_JAK_STAT3_SIGNALING+0.530
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- INFLAMMATORY_RESPONSE+0.490
- COMPLEMENT+0.450
- TNFA_SIGNALING_VIA_NFKB+0.430
- COAGULATION+0.410
- KRAS_SIGNALING_UP+0.410
Top 10 suppressed
- MYC_TARGETS_V1-0.460
- E2F_TARGETS-0.450
- MYC_TARGETS_V2-0.390
- DNA_REPAIR-0.360
- G2M_CHECKPOINT-0.330
- OXIDATIVE_PHOSPHORYLATION-0.330
- CHOLESTEROL_HOMEOSTASIS-0.270
- PROTEIN_SECRETION-0.230
- MTORC1_SIGNALING-0.220
- PEROXISOME-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-L9-A743-01A-43R-A39D-07 | — | cohortA1 | 0.944 |
| 2 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.934 |
| 3 | C3N-02923 | — | cohortMD2 | 0.934 |
| 4 | TCGA-CN-4733-01A-02R-1873-07 | — | — | 0.926 |
| 5 | cf9ea065-c101-48e2-a1ea-54eb01658eef | — | — | 0.925 |
| 6 | TCGA-D8-A141-01A-11R-A115-07 | — | A | 0.923 |
| 7 | TCGA-77-A5FZ-01A-31R-A27Q-07 | — | cohortMD2 | 0.921 |
| 8 | TCGA-60-2697-01A-11R-2125-07 | — | cohortMD2 | 0.920 |
| 9 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.919 |
| 10 | MDT-AP-3277 | Med | Medulloblastoma | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.610 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.580 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.530 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| COMPLEMENT | 0.450 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |